Biologic medications account for the majority of outpatient treatment expenditures for inflammatory bowel disease.1 The US Food and Drug Administration (FDA) approved adalimumab (Humira, AbbVie Inc) for Crohn disease (CD) in 2007 and ulcerative colitis (UC) in 2012 and approved certolizumab (Cimzia, Union Chimique Belge) for CD in 2006.
For Medicare beneficiaries, adalimumab and certolizumab are the biologic agents prescribed by the largest number of gastroenterologists. These gastroenterologists frequently receive payments from the manufacturers of high-revenue medications.2,3 We investigated the association between payments from the manufacturers of these drugs to gastroenterologists and Medicare spending on these drugs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians. JAMA Intern Med. Published online July 08, 2019. doi:10.1001/jamainternmed.2019.0999
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: